Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Talpaz, M' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 256 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Shimoni, A; Gajewski, J; Donato, M; Martin, T; O'Brien, S; Talpaz, M; Cohen, A; Korbling, M; Champlin, R; Giralt, S
      Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    2. Giles, FJ; Kantarjian, H; O'Brien, S; Rios, MB; Cortes, J; Beran, M; Koller, C; Keating, M; Talpaz, M
      Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase

      LEUKEMIA & LYMPHOMA
    3. Gordon, MS; Margolin, K; Talpaz, M; Sledge, GW; Holmgren, E; Benjamin, R; Stalter, S; Shak, S; Adelman, DC
      Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    4. Kurzrock, R; Cortes, J; Thomas, DA; Jeha, S; Pilat, S; Talpaz, M
      Pilot study of low-dose interleukin-11 in patients with bone marrow failure

      JOURNAL OF CLINICAL ONCOLOGY
    5. Kurzrock, R; Bueso-Ramos, CE; Kantarjian, H; Freireich, E; Tucker, SL; Siciliano, M; Pilat, S; Talpaz, M
      BCR rearrangement-negative chronic myelogenous leukemia revisited

      JOURNAL OF CLINICAL ONCOLOGY
    6. Kalidas, MT; Kantarjian, H; Talpaz, M
      Chronic myelogenous leukemia

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    7. Talpaz, M
      Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition

      SEMINARS IN HEMATOLOGY
    8. Druker, BJ; Talpaz, M; Resta, DJ; Peng, B; Buchdunger, E; Ford, JM; Lydon, NB; Kantarjian, H; Capdeville, R; Ohno-Jones, S; Sawyers, CL
      Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia.

      NEW ENGLAND JOURNAL OF MEDICINE
    9. Druker, BJ; Sawyers, CL; Kantarjian, H; Resta, DJ; Reese, SF; Ford, JM; Capdeville, R; Talpaz, M
      Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe philadelphia chromosome.

      NEW ENGLAND JOURNAL OF MEDICINE
    10. Laurent, E; Talpaz, M; Kantarjian, H; Kurzrock, R
      The BCR gene and Philadelphia chromosome-positive leukemogenesis

      CANCER RESEARCH
    11. Wang, Y; Liu, JX; Wu, Y; Luo, WP; Lin, SH; Lin, H; Hawk, N; Sun, T; Guo, JQ; Estrov, Z; Talpaz, M; Champlin, R; Arlinghaus, RB
      Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death

      CANCER RESEARCH
    12. Kantarjian, HM; Talpaz, M; Santini, V; Murgo, A; Cheson, B; O'Brien, SM
      Homoharringtonine - History, current research, and future directions

      CANCER
    13. Kantarjian, HM; Shan, JQ; Smith, T; Talpaz, M; Kozuch, P; Rios, MB; Cortes, J; Giles, FJ; O'Brien, S
      Response to therapy is independently associated with survival prolongationin chronic myelogenous leukemia in the blastic phase

      CANCER
    14. Ravandi, F; Hayes, K; Cortes, J; Albitar, M; Glassman, A; Talpaz, M; Kantarjian, HM
      Translocation t(17;18)(q10;q10) - A new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia

      CANCER
    15. Ravandi, F; Kantarjian, HM; Talpaz, M; O'Brien, S; Faderl, S; Giles, FJ; Thomas, D; Cortes, J; Andreeff, M; Estrov, Z; Rios, MB; Albitar, M
      Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance

      CANCER
    16. Talpaz, M; O'Brien, S; Rose, E; Gupta, S; Shan, JQ; Cortes, J; Giles, FJ; Faderl, S; Kantarjian, HM
      Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia

      BLOOD
    17. Kardinal, C; Konkol, B; Lin, H; Eulitz, M; Schmidt, EK; Estrov, Z; Talpaz, M; Arlinghaus, RB; Feller, SM
      Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes

      BLOOD
    18. Gisslinger, H; Kurzrock, R; Gisslinger, B; Jiang, SW; Li, SR; Virgolini, I; Woloszczuk, W; Andreeff, M; Talpaz, M
      Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor

      BLOOD
    19. Donato, NJ; Wu, JY; Zhang, L; Kantarjian, H; Talpaz, M
      Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulatingfactor receptor beta-chain in BCR-ABL(+) human leukemic cells: associationwith loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition

      BLOOD
    20. Donato, NJ; Talpaz, M
      Clinical use of tyrosine kinase inhibitors: Therapy for chronic myelogenous leukemia and other cancers

      CLINICAL CANCER RESEARCH
    21. Reuben, JM; Lee, BN; Johnson, H; Fritsche, H; Kantarjian, HM; Talpaz, M
      Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha

      CLINICAL CANCER RESEARCH
    22. Rodriguez, J; Cortes, J; Talpaz, M; O'Brien, S; Smith, TL; Rios, MB; Kantarjian, H
      Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia

      CLINICAL CANCER RESEARCH
    23. Tannir, NM; Talpaz, M; Ghazal, H; Proothi, S; Kantarjian, HM
      Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia

      LEUKEMIA & LYMPHOMA
    24. Faderl, S; Kantarjian, HM; Talpaz, M; Estrov, Z
      Clinical significance of minimal residual disease in leukemia (Review)

      INTERNATIONAL JOURNAL OF ONCOLOGY
    25. Kardinal, C; Konkol, B; Schulz, A; Posern, G; Lin, H; Adermann, K; Eulitz, M; Estrov, Z; Talpaz, M; Arlinghaus, RB; Feller, SM
      Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients

      FASEB JOURNAL
    26. Talpaz, M; Berman, E; Clift, RA; Copelan, EA; Emanuel, PD; Erba, HP; Glenn, MJ; Greenberg, PL; Jones, RJ; O'Brien, S; Saba, HI; Schilder, R; Snyder, DS; Soiffer, RJ; Tallman, MS; Wetzler, M; Ravandi-Kashani, F; Kantarjian, H; Talpaz, M
      NCCN Practice Guidelines for chronic myelogenous leukemia

      ONCOLOGY-NEW YORK
    27. Talpaz, M; Qiu, X; Cheng, K; Cortes, JE; Kantarjian, H; Kurzrock, R
      Autoantibodies to Abl and Bcr proteins

      LEUKEMIA
    28. Laurent, E; Talpaz, M; Wetzler, M; Kurzrock, R
      Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins

      LEUKEMIA
    29. Kantarjian, HM; Talpaz, M; Smith, TL; Cortes, J; Giles, FJ; Rios, MB; Mallard, S; Gajewski, A; Murgo, A; Cheson, B; O'Brien, S
      Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    30. Faderl, S; Kantarjian, HM; Talpaz, M; O'Brien, S
      New treatment approaches for chronic myelogenous leukemia

      SEMINARS IN ONCOLOGY
    31. Kozuch, P; Talpaz, M; Faderl, S; O'Brien, S; Freireich, EJ; Kantarjian, H
      Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha - A synergistic correlation?

      CANCER
    32. Kaban, K; Kantarjian, H; Talpaz, M; O'Brien, S; Cortes, J; Giles, FJ; Pierce, S; Albitar, M
      Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia - Correlation with disease progression and response to therapy

      CANCER
    33. Farhad, R; Cortes, J; Albitar, M; Arlinghaus, R; Guo, JQ; Talpaz, M; Kantarjian, HM
      Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance (vol 107, pg 581, 1999)

      BRITISH JOURNAL OF HAEMATOLOGY
    34. Giles, FJ; Keating, AR; Kurzrock, R; Talpaz, M
      A pilot study of recombinant human interleukin-4 therapy of myelofibrosis

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    35. Ravandi, F; Estrov, Z; Kurzrock, R; Breitmeyer, JB; Maschek, BJ; Talpaz, M
      A phase I study of recombinant interferon-beta in patients with advanced malignant disease

      CLINICAL CANCER RESEARCH
    36. Faderl, S; Thall, PF; Kantarjian, HM; Talpaz, M; Harris, D; Van, Q; Beran, M; Kornblau, SM; Pierce, S; Estrov, Z
      Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia

      CLINICAL CANCER RESEARCH
    37. Kantarjian, HM; Talpaz, M; O'Brien, S; Manshouri, T; Cortes, J; Giles, F; Rios, MB; Croce, CM; Albitar, M
      Significance of FHIT expression in chronic myelogenous leukemia

      CLINICAL CANCER RESEARCH
    38. Sacchi, S; Kantarjian, HM; Freireich, EJ; O'Brien, SO; Cortes, J; Rios, MB; Kornblau, S; Giles, FJ; Koller, C; Gajewski, J; Talpaz, M
      Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia

      LEUKEMIA & LYMPHOMA
    39. Ravandi-Kashani, F; Cortes, J; Cohen, P; Talpaz, M; O'Brien, S; Markowitz, A; Kantarjian, H
      Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferativedisorders

      LEUKEMIA & LYMPHOMA
    40. Seong, D; Kantarjian, HM; Albitar, M; Arlinghaus, R; Xu, J; Talpaz, M; Rios, MB; Guo, JQ; O'Brien, S; Siciliano, M
      Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

      ANNALS OF ONCOLOGY
    41. Faderl, S; Kantarjian, HM; Talpaz, M
      Chronic myelogenous leukemia: Update on biology and treatment

      ONCOLOGY-NEW YORK
    42. Kantarjian, HM; O'Brien, S; Smith, TL; Rios, MB; Cortes, J; Beran, M; Koller, C; Giles, FJ; Andreeff, M; Kornblau, S; Giralt, S; Keating, MJ; Talpaz, M
      Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

      JOURNAL OF CLINICAL ONCOLOGY
    43. Faderl, S; Talpaz, M; Estrov, Z; O'Brien, S; Kurzrock, R; Kantarjian, HM
      Mechanisms of disease - The biology of chronic myeloid leukemia

      NEW ENGLAND JOURNAL OF MEDICINE
    44. Beaupre, DM; Talpaz, M; Marini, FC; Cristiano, RJ; Roth, JA; Estrov, Z; Albitar, M; Freedman, MH; Kurzrock, R
      Autocrine interleukin-1 beta production in leukemia: Evidence for the involvement of mutated RAS

      CANCER RESEARCH
    45. Giles, FJ; Kantarjian, HM; Cortes, J; Thomas, DA; Talpaz, M; Manshouri, T; Albitar, M
      Multidrug resistance protein expression in chronic myeloid leukemia - Associations and significance

      CANCER
    46. Sacchi, S; Kantarjian, HM; O'Brien, S; Cortes, J; Rios, MB; Giles, FJ; Beran, M; Koller, CA; Keating, MJ; Talpaz, M
      Chronic myelogenous leukemia in nonlymphoid blastic phase - Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

      CANCER
    47. Ravandi-Kashani, F; Cortes, J; Talpaz, M; Kantarjian, HM
      Thrombotic microangiopathy associated with interferon therapy for patientswith chronic myelogenous leukemia - Coincidence or true side effect?

      CANCER
    48. Ravandi, F; Cortes, J; Albitar, M; Arlinghaus, R; Guo, JQ; Talpaz, M; Kantarjian, HM
      Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance

      BRITISH JOURNAL OF HAEMATOLOGY
    49. Estrov, Z; Manna, SK; Harris, D; Van, Q; Estey, EH; Kantarjian, HM; Talpaz, M; Aggarwal, BB
      Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells

      BLOOD
    50. Silver, RT; Woolf, SH; Hehlmann, R; Appelbaum, FR; Anderson, J; Bennett, C; Goldman, JM; Guilhot, F; Kantarjian, HM; Lichtin, AE; Talpaz, M; Tura, S
      An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology

      BLOOD
    51. Faderl, S; Talpaz, M; Kantarjian, HM; Estrov, Z
      Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making - Response

      BLOOD
    52. Faderl, S; Talpaz, M; Kantarjian, HM; Estrov, Z
      Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia - Response

      BLOOD
    53. Faderl, S; Talpaz, M; Kantarjian, HM; Estrov, Z
      Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?

      BLOOD
    54. Issa, JPJ; Kantarjian, H; Mohan, A; O'Brien, S; Cortes, J; Pierce, S; Talpaz, M
      Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance

      BLOOD
    55. O'Brien, S; Kantarjian, H; Koller, C; Feldman, E; Beran, M; Andreeff, M; Giralt, S; Cheson, B; Keating, M; Freireich, E; Rios, MB; Talpaz, M
      Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia

      BLOOD
    56. Faderl, S; Talpaz, M; Estrov, Z; Kantarjian, HM
      Chronic myelogenous leukemia: Biology and therapy

      ANNALS OF INTERNAL MEDICINE
    57. TALPAZ M; KURZROCK R; KANTARJIAN H
      THE CLINICAL IMPACT OF INTERFERON USAGE IN HEMATOLOGIC MALIGNANCIES

      European cytokine network
    58. SACCHI S; CORTES J; KANTARJIAN H; TALPAZ M
      EFFECTS OF INTERFERON-ALPHA THERAPY ON LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA

      Hematopathology and molecular hematology
    59. KRAINICK U; KANTARJIAN H; BROUSSARD S; TALPAZ M
      LOCAL CUTANEOUS NECROTIZING LESIONS ASSOCIATED WITH INTERFERON INJECTIONS

      Journal of interferon & cytokine research
    60. BERAN M; CAO XB; ESTROV Z; JEHA S; JIN GZ; OBRIEN S; TALPAZ M; ARLINGHAUS RB; LYDON NB; KANTARJIAN H
      SELECTIVE-INHIBITION OF CELL-PROLIFERATION AND BCR-ABL PHOSPHORYLATION IN ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS EXPRESSING M-R-190,000 BCR-ABLPROTEIN BY A TYROSINE KINASE INHIBITOR (CGP-57148)

      Clinical cancer research
    61. SEONG D; THALL P; KANTARJIAN HM; TALPAZ M; SWANTKOWSKI J; XU JP; SHEN Y; GLASSMAN A; RAMAGLI L; SICILIANO MJ
      PHILADELPHIA-CHROMOSOME-POSITIVE MYELOID CELLS IN THE PERIPHERAL-BLOOD OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS - COMPARISON WITH THE FREQUENCY DETECTED IN CYCLING CELLS OF THE BONE-MARROW

      Clinical cancer research
    62. SEONG D; THALL P; KANTARJIAN HM; TALPAZ M; SWANTKOWSKI J; XU JP; SHEN Y; GLASSMAN A; RAMAGLI L; SICILIANO MJ
      PHILADELPHIA-CHROMOSOME-POSITIVE MYELOID CELLS IN THE PERIPHERAL-BLOOD OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS - COMPARISON WITH THE FREQUENCY DETECTED IN CYCLING CELLS OF THE BONE-MARROW

      Clinical cancer research
    63. FAYAD L; CABANILLAS F; TALPAZ M; MCLAUGHLIN P; KURZROCK R
      HIGH SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH A SHORTER FAILURE-FREESURVIVAL IN INDOLENT LYMPHOMA

      Leukemia & lymphoma
    64. WRIGHTBROWNE V; SCHNEE AM; JENKINS MA; THALL PF; AGGARWAL BB; TALPAZ M; ESTROV Z
      SERUM CYTOKINE LEVELS IN INFECTIOUS-MONONUCLEOSIS AT DIAGNOSIS AND CONVALESCENCE

      Leukemia & lymphoma
    65. FERRAJOLI A; TALPAZ M; KURZROCK R; HARRIS D; VAN Q; ESTEY EH; ESTROV Z
      THROMBOPOIETIN STIMULATES MYELODYSPLASTIC SYNDROME GRANULOCYTE-MACROPHAGE AND ERYTHROID PROGENITOR PROLIFERATION

      Leukemia & lymphoma
    66. KANTARJIAN HM; GILES FJ; OBRIEN SM; TALPAZ M
      CLINICAL COURSE AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA AND CHEMOTHERAPY

      Hematology/oncology clinics of North America
    67. CORTES J; KANTARJIAN H; OBRIEN S; KURZROCK R; KEATING M; TALPAZ M
      GM-CSF CAN IMPROVE THE CYTOGENETIC RESPONSE OBTAINED WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    68. CORTES J; FAYAD L; KANTARJIAN H; OBRIEN S; LEE MS; TALPAZ M
      ASSOCIATION OF HLA PHENOTYPE AND RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    69. OKA T; SASTRY KJ; NEHETE P; SCHAPIRO SJ; GUO JQ; TALPAZ M; ARLINGHAUS RB
      EVIDENCE FOR SPECIFIC IMMUNE-RESPONSE AGAINST P210 BCR-ABL IN LONG-TERM REMISSION CML PATIENTS TREATED WITH INTERFERON

      Leukemia
    70. KURZROCK R; TALPAZ M; BERAN M; HARRIS D; ESTROV Z
      DNA IN-SITU HYBRIDIZATION OF INDIVIDUAL COLONIES TO DETERMINE LINEAGEDERIVATION IN LEUKEMIA

      Leukemia
    71. WILHELM M; BUESORAMOS C; OBRIEN S; PIERCE S; KEATING M; TALPAZ M; KANTARJIAN HM
      EFFECT OF INTERFERON-ALPHA THERAPY ON BONE-MARROW FIBROSIS IN CHRONICMYELOGENOUS LEUKEMIA

      Leukemia
    72. GANDHI V; PLUNKETT W; KANTARJIAN H; TALPAZ M; ROBERTSON LE; OBRIEN S
      CELLULAR PHARMACODYNAMICS AND PLASMA PHARMACOKINETICS OF PARENTERALLYINFUSED HYDROXYUREA DURING A PHASE-I CLINICAL-TRIAL IN CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    73. KURZROCK R; ESTROV Z; KANTARJIAN H; TALPAZ M
      CONVERSION OF INTERFERON-INDUCED, LONG-TERM CYTOGENETIC REMISSIONS INCHRONIC MYELOGENOUS LEUKEMIA TO POLYMERASE-CHAIN-REACTION NEGATIVITY

      Journal of clinical oncology
    74. SACCHI S; KANTARJIAN HM; SMITH TL; OBRIEN S; PIERCE S; KORNBLAU S; BERAN M; KEATING MJ; TALPAZ M
      EARLY TREATMENT DECISIONS WITH INTERFERON-ALPHA THERAPY IN EARLY CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    75. CORTES J; TALPAZ M; OBRIEN S; RIOS MB; MAJLIS A; KEATING M; FREIREICH EJ; KANTARJIAN H
      SUPPRESSION OF CYTOGENETIC CLONAL EVOLUTION WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    76. Rodriguez, J; Cortes, J; Smith, T; O'Brien, S; Rios, MB; Talpaz, M; Kantarjian, H
      Determinants of prognosis in late chronic-phase chronic myelogenous leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    77. ESTROV Z; TALPAZ M; KU S; HARRIS D; VAN Q; BERAN M; HIRSCHGINSBERG C; HUH Y; YEE G; KURZROCK R
      Z-138 - A NEW MATURE B-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA CELL-LINE FROM A PATIENT WITH TRANSFORMED CHRONIC LYMPHOCYTIC-LEUKEMIA

      Leukemia research
    78. KURZROCK R; ESTROV Z; KU S; LEONARD M; TALPAZ M
      INTERLEUKIN-1 INCREASES EXPRESSION OF THE LYT-10 (NF-KAPPA-B2) PROTOONCOGENE TRANSCRIPTION FACTOR IN RENAL-CELL CARCINOMA LINES

      The Journal of laboratory and clinical medicine
    79. ARLINGHAUS RB; LIU J; WU Y; MA G; LIN SH; ESTROV Z; TALPAZ M
      BCR IS A CONDITIONAL NEGATIVE REGULATOR OF BCR-ABL INDUCED LEUKEMIAS

      British Journal of Haematology
    80. ESTROV Z; THALL PF; TALPAZ M; ESTEY EH; KANTARJIAN HM; ANDREEFF M; HARRIS D; VAN Q; WALTERSCHEID M; KORNBLAU SM
      CASPASE-2 AND CASPASE-3 PROTEIN-LEVELS AS PREDICTORS OF SURVIVAL IN ACUTE MYELOGENOUS LEUKEMIA

      Blood
    81. KANTARJIAN HM; TALPAZ M
      QUESTIONS RAISED BY THE BENELUX CML STUDY-GROUP - RESULTS FROM THE RANDOMIZED STUDY WITH HYDROXYUREA ALONE VERSUS HYDROXYUREA COMBINED WITHLOW-DOSE INTERFERON-ALPHA-2B FOR CHRONIC MYELOID-LEUKEMIA

      Blood
    82. RANDHAWA GS; CUI HM; BARLETTA JA; STRICHMANALMASHANU LZ; TALPAZ M; KANTARJIAN H; DEISSEROTH AB; CHAMPLIN RC; FEINBERG AP
      LOSS OF IMPRINTING IN DISEASE PROGRESSION IN CHRONIC MYELOGENOUS LEUKEMIA

      Blood
    83. FADERL S; KANTARJIAN HM; TALPAZ M; ESTROV Z
      CLINICAL-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA

      Blood
    84. KANTARJIAN HM; TALPAZ M; OBRIEN S; KURZROCK R; GUTTERMAN J; KEATING MJ; MCCREDIE KB; FREIREICH EJ
      CHRONIC MYELOGENOUS LEUKEMIA - PROGRESS AT THE M.-D.-ANDERSON-CANCER-CENTER OVER THE PAST 2 DECADES AND FUTURE-DIRECTIONS - FIRST FREIREICH,EMIL,J AWARD LECTURE

      Clinical cancer research
    85. GISSLINGER H; KURZROCK R; WETZLER M; TUCKER S; KANTARJIAN H; ROBERTSON B; TALPAZ M
      APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA - STUDIES OF STAGE-SPECIFICDIFFERENCES

      Leukemia & lymphoma
    86. ESTROV Z; TALPAZ M
      ROLE OF INTERLEUKIN-1-BETA CONVERTING-ENZYME (ICE) IN ACUTE MYELOGENOUS LEUKEMIA-CELL PROLIFERATION AND PROGRAMMED CELL-DEATH

      Leukemia & lymphoma
    87. CORTES J; KANTARJIAN HM; GIRALT S; TALPAZ M
      NATURAL-HISTORY AND STAGING OF CHRONIC MYELOGENOUS LEUKEMIA

      Bailliere's clinical haematology
    88. TALPAZ M; KANTARJIAN HM; OBRIEN S; KURZROCK R
      THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE WITH INTERFERON-ALPHA THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA

      Bailliere's clinical haematology
    89. BSEISO AW; KANTARJIAN HM; GUO JQ; CORTES J; TALPAZ M; KOLLER C; ALBITAR M; KEATING M; ARLINGHAUS R
      ANALYSIS OF THE BCR-ABL PROTEIN IN PHILADELPHIA-CHROMOSOME-POSITIVE ADULT ACUTE LYMPHOCYTIC-LEUKEMIA

      Leukemia
    90. CORTES J; KANTARJIAN H; OBRIEN S; BERAN M; ESTEY E; KEATING M; TALPAZ M
      A PILOT-STUDY OF ALL-TRANS-RETINOIC ACID IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    91. CORTES J; KANTARJIAN H; TALPAZ M; OBRIAN S; BERAN M; KOLLER C; KEATING M
      TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA WITH NUCLEOSIDE ANALOGS DEOXYCOFORMYCIN AND FLUDARABINE

      Leukemia
    92. FAYAD L; KANTARJIAN H; OBRIEN S; SEONG D; ALBITAR M; KEATING M; TALPAZ M
      EMERGENCE OF NEW CLONAL ABNORMALITIES FOLLOWING INTERFERON-ALPHA INDUCED COMPLETE CYTOGENETIC RESPONSE IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA - REPORT OF 3 CASES

      Leukemia
    93. SACCHI S; KANTARJIAN HM; OBRIEN S; BERAN M; KOLLER C; PIERCE S; KORNBLAU S; ESTEY E; KEATING MJ; TALPAZ M
      LONG-TERM FOLLOW-UP RESULTS OF ALPHA-INTERFERON-BASED REGIMENS IN PATIENTS WITH LATE CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    94. KANTARJIAN HM; OBRIEN SM; KEATING M; BERAN M; ESTEY E; GIRALT S; KORNBLAU S; RIOS MB; DEVOS D; TALPAZ M
      RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    95. OBRIEN S; KANTARJIAN H; BERAN M; KOLLER C; TALPAZ M; LERNER S; KEATING MJ
      FLUDARABINE AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

      Leukemia
    96. SEYMOUR JF; TALPAZ M; KURZROCK R
      RESPONSE DURATION AND RECOVERY OF CD4(-ALPHA-RESISTANT HAIRY-CELL LEUKEMIA - 7-YEAR FOLLOW-UP() LYMPHOCYTES FOLLOWING DEOXYCOFORMYCIN IN INTERFERON)

      Leukemia
    97. KANTARJIAN HM; OBRIEN SM; ESTEY E; GIRALT S; BERAN M; RIOS MB; KEATING M; DEVOS D; TALPAZ M
      DECITABINE STUDIES IN CHRONIC AND ACUTE MYELOGENOUS LEUKEMIA

      Leukemia
    98. KURZROCK R; STROM SS; ESTEY E; OBRIEN S; KEATING MJ; JIANG H; ADAMS T; TALPAZ M
      2ND CANCER RISK IN HAIRY-CELL LEUKEMIA - ANALYSIS OF 350 PATIENTS

      Journal of clinical oncology
    99. WETZLER M; KURZROCK R; ESTROV Z; BARONE S; ESTEY E; TALPAZ M
      SUPPRESSED FORMATION OF BONE-MARROW ADHERENT LAYERS DERIVED FROM ACUTE MYELOID-LEUKEMIA PATIENTS AFTER IN-VITRO EXPOSURE TO INTERLEUKIN-4

      Leukemia research
    100. WRIGHTBROWNE V; MCCLAIN KL; TALPAZ M; ORDONEZ N; ESTROV Z
      PHYSIOLOGY AND PATHOPHYSIOLOGY OF DENDRITIC CELLS

      Human pathology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/10/20 alle ore 12:44:45